Skip to main content
SpringerLink
Log in
Book cover

Biomarkers for Alzheimer’s Disease Drug Development pp 203–212Cite as

Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1750))

Abstract

Amyloid plaques are a neuropathologic hallmark of Alzheimer’s disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including 11C-Pittsburgh compound B and the 18F-labeled compounds such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 7:270–279

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629

    Article  PubMed  Google Scholar 

  3. Teipel S, Drzezga A, Grothe MJ et al (2015) Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol 14:1037–1353

    Article  PubMed  Google Scholar 

  4. Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:11–15

    Article  Google Scholar 

  5. Guerra UP, Nobili FM, Padovani A et al (2015) Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci 36:1075–1081

    Article  PubMed  Google Scholar 

  6. Minoshima S, Drzezga AE, Barthel H et al (2016) SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 57:1316–1322

    Article  CAS  PubMed  Google Scholar 

  7. Garibotto V, Morbelli S, Pagani M (2016) Erratum to: dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging 43:1747

    Article  PubMed  Google Scholar 

  8. Magistretti PJ (2000) Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res 886:108–112

    Article  CAS  PubMed  Google Scholar 

  9. Ni R, Gillberg PG, Bergfors A et al (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136:2217–2227

    Article  PubMed  Google Scholar 

  10. Hsiao IT, Huang CC, Hsieh CJ et al (2012) Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 39:613–620

    Article  CAS  PubMed  Google Scholar 

  11. Koole M, Lewis DM, Buckley C et al (2009) Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50:818–822

    Article  CAS  PubMed  Google Scholar 

  12. O’Keefe GJ, Saunder TH, Ng S et al (2009) Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50:309–315

    Article  PubMed  Google Scholar 

  13. Chincarini A, Sensi F, Rei L et al (2016) Alzheimer’s Disease Neuroimaging Initiative. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis 54:1437–1457

    Article  CAS  PubMed  Google Scholar 

  14. Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31:496–505

    Article  PubMed  PubMed Central  Google Scholar 

  15. Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11:669–678

    Article  CAS  PubMed  Google Scholar 

  16. Landau SM, Thomas BA, Thurfjell L et al (2014) Alzheimer’s Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41:1398–1407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. van Berckel BN, Ossenkoppele R, Tolboom N et al (2013) Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54:1570–1576

    Article  CAS  PubMed  Google Scholar 

  18. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746

    Article  PubMed  Google Scholar 

  19. Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 9:e-1–e-16

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genova, Italy

    Silvia Morbelli & Matteo Bauckneht

  2. Department of Health Sciences, University of Genoa, Genoa, Italy

    Silvia Morbelli & Matteo Bauckneht

Authors
  1. Silvia Morbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Bauckneht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Morbelli .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Robert Perneczky

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Morbelli, S., Bauckneht, M. (2018). Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers. In: Perneczky, R. (eds) Biomarkers for Alzheimer’s Disease Drug Development. Methods in Molecular Biology, vol 1750. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7704-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7704-8_13

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7703-1

  • Online ISBN: 978-1-4939-7704-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation